and Drugs for Vulvovaginal Candidiasis Market

The cell wall of Candida is a complex glycoprotein that depends on the biosynthesis of ergosterol. Azole compounds, found in antimycotic drugs, are believed to block ergosterol production, allowing topical antimycotics to achieve cure rates in excess of 80%. The only oral azole agent approved for this indication by the US Food and Drug Administration (FDA) is fluconazole, which also achieves a high cure rate. Therapeutic concentrations are found in vaginal secretions for at least 72 hours after the ingestion of a single 150-mg tablet.

Scope of the Report:
and Drugs for Vulvovaginal Candidiasis Market focuses on the Drugs for Vulvovaginal Candidiasis in North America and Europe market, especially in United States, United Kingdom, Canada, Germany, France, Italy and Spain. and Drugs for Vulvovaginal Candidiasis Market categorizes the market based on manufacturers, countries/Regions, type and application.
Market Segment by Manufacturers, and Drugs for Vulvovaginal Candidiasis Market covers
Bayer
Perrigo
J & J
Pfizer
Bristol-Myers Squibb
Effik
Teva
Sanofi
Cisen Pharmaceutical
Kingyork Group

Market Segment by Countries, covering
United States
United Kingdom
Canada
Germany
France
Italy
Spain

Market Segment by Type, covers
Miconazole
Clotrimazole
Fluconazole
Econazole
Other

Market Segment by Applications, can be divided into
Hospital & Clinic
Pharmacy

There are 19 Chapters to deeply display the North America and Europe Drugs for Vulvovaginal Candidiasis market.

Chapter 1, to describe Drugs for Vulvovaginal Candidiasis Introduction, product type and application, market overview, market analysis by countries, market opportunities, market risk, market driving force;

Chapter 2, to analyze the manufacturers of Drugs for Vulvovaginal Candidiasis, with profile, main business, news, sales, price, revenue and market share in 2020 and 2021;

Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2020 and 2021;

Chapter 4, to show the North America and Europe market by countries, covering United States, United Kingdom, Canada, France, Germany, Italy and Spain, with sales, price, revenue and market share of Drugs for Vulvovaginal Candidiasis, for each country, from 2017 to 2022;

Chapter 5 and 6, to show the market by type and application, with sales, price, revenue, market share and growth rate by type, application, from 2017 to 2022;

Chapter 7, 8, 9, 10, 11, 12 and 13 to analyze the key countries by manufacturers, Type and Application, covering 7 countries, with sales, revenue and market share by manufacturers, types and applications;

Chapter 14, Drugs for Vulvovaginal Candidiasis market forecast, by countries, type and application, with sales, price, revenue and growth rate forecast, from 2022 to 2028;

Chapter 15, to analyze the manufacturing cost, key raw materials and manufacturing process, etc.

Chapter 16, to analyze the industrial chain, sourcing strategy and downstream end users (buyers);

Chapter 17, to describe sales channel, distributors, traders, dealers, etc.

Chapter 18 and 19, to describe the research findings and conclusion, appendix, methodology and data source.